Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603705 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
A Phase 3 study, sponsored by Egalet.
- Completed
- Registry status
- Phase 3
- Development phase
- 281
- Enrollment target
NCT02603705 is a Phase 3 study that has completed, run by Egalet. The registered enrollment target is 281 participants.
The verdict
NCT02603705, a Phase 3 study, has completed, sponsored by Egalet.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 281 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
Interventions
- DRUG Oxycodone extended-release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2016-03-07 |
| Est. Completion | 2017-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603705
The ClinicalTrials.gov registry entry for NCT02603705 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 281 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Egalet, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxycodone extended-release is the first listed.
NCT02603705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603705 about?
NCT02603705 is a clinical study titled "Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain". The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
What is the current status of trial NCT02603705?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 281 participants. The study started on 2016-03-07. Estimated completion is 2017-06-15.
What interventions are being tested in trial NCT02603705?
The interventions under investigation include: Oxycodone extended-release (DRUG).
Who is sponsoring clinical trial NCT02603705?
This trial is sponsored by Egalet, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.